Amoéba S.A. Logo

Amoéba S.A.

ALMIB.PA

(1.5)
Stock Price

0,70 EUR

-64.33% ROA

-292.35% ROE

-0.01x PER

Market Cap.

26.071.500,00 EUR

-112.67% DER

0% Yield

0% NPM

Amoéba S.A. Stock Analysis

Amoéba S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Amoéba S.A. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (29%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-198.11%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-83.78%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Amoéba S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Amoéba S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Amoéba S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Amoéba S.A. Revenue
Year Revenue Growth
2012 81.517
2013 302.211 73.03%
2014 222.484 -35.83%
2015 141 -158817.14%
2016 126 -12%
2017 161 22.36%
2018 122 -31.97%
2019 122.480 99.9%
2019 122.480 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Amoéba S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2012 390.737
2013 679.092 42.46%
2014 970.668 30.04%
2015 1.485 -65308.89%
2016 2.640 43.77%
2017 2.689 1.86%
2018 1.553 -73.15%
2019 2.612.858 99.94%
2019 1.249.399 -109.13%
2020 1.338.001 6.62%
2021 2.015.667 33.62%
2022 2.214.617 8.98%
2023 4.401 -50232.2%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Amoéba S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 207.294
2013 238.749 13.17%
2014 503.108 52.55%
2015 1.953 -25660.78%
2016 1.955 0.1%
2017 2.463 20.63%
2018 2.555 3.6%
2019 1.379.601 99.81%
2019 2.470 -55754.29%
2020 3.783 34.69%
2021 2.956 -27.94%
2022 2.209 -33.82%
2023 4.195 47.34%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Amoéba S.A. EBITDA
Year EBITDA Growth
2012 -146.922
2013 -411.000 64.25%
2014 -808.703 49.18%
2015 -3.845 -20938.06%
2016 -5.524 30.41%
2017 -5.266 -4.9%
2018 -4.734 -11.26%
2019 -3.299.479 99.86%
2019 -3.719.780 11.3%
2020 -5.186.020 28.27%
2021 -5.293.900 2.04%
2022 -5.291.040 -0.05%
2023 -9.800 -53895.71%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Amoéba S.A. Gross Profit
Year Gross Profit Growth
2012 81.517
2013 302.211 73.03%
2014 222.484 -35.83%
2015 -121 183971.07%
2016 -455 73.41%
2017 -499 8.82%
2018 -869 42.58%
2019 -580.717 99.85%
2019 -2.227.445 73.93%
2020 -1.465.965 -51.94%
2021 -858.947 -70.67%
2022 -1.013.350 15.24%
2023 -3.001 -33678.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Amoéba S.A. Net Profit
Year Net Profit Growth
2012 -246.919
2013 -521.093 52.62%
2014 -974.637 46.53%
2015 -4.019 -24156.77%
2016 -5.768 30.33%
2017 -6.234 7.48%
2018 -7.223 13.69%
2019 -9.038.141 99.92%
2019 -7.249.714 -24.67%
2020 -8.157.109 11.12%
2021 -7.817.294 -4.35%
2022 -8.022.894 2.56%
2023 -41.184 -19381.08%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Amoéba S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 -1 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2019 -1 0%
2020 -1 0%
2021 0 0%
2022 0 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Amoéba S.A. Free Cashflow
Year Free Cashflow Growth
2012 -632.386
2013 -21.455 -2847.5%
2014 -2.086.124 98.97%
2015 -5.591 -37218.86%
2016 -8.928 37.39%
2017 -5.966 -49.65%
2018 -5.394 -10.62%
2019 -3.708.496 99.85%
2019 -878.438 -322.17%
2020 -3.518.093 75.03%
2021 -6.046.327 41.81%
2022 -5.707.796 -5.93%
2023 -8.998 -63334.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Amoéba S.A. Operating Cashflow
Year Operating Cashflow Growth
2012 -162.555
2013 500.206 132.5%
2014 -1.193.009 141.93%
2015 -4.165 -28550.55%
2016 -5.706 27.01%
2017 -5.079 -12.33%
2018 -5.330 4.71%
2019 -3.635.012 99.85%
2019 -860.067 -322.64%
2020 -3.457.089 75.12%
2021 -5.901.752 41.42%
2022 -5.402.126 -9.25%
2023 -4.282 -126058.94%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Amoéba S.A. Capital Expenditure
Year Capital Expenditure Growth
2012 469.831
2013 521.661 9.94%
2014 893.115 41.59%
2015 1.426 -62574.74%
2016 3.223 55.77%
2017 887 -263.25%
2018 63 -1307.94%
2019 73.484 99.91%
2019 18.371 -300%
2020 61.004 69.89%
2021 144.575 57.8%
2022 305.670 52.7%
2023 4.716 -6382.93%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Amoéba S.A. Equity
Year Equity Growth
2011 597.418
2012 947.195 36.93%
2013 433.989 -118.25%
2014 2.799.017 84.49%
2015 10.598 -26310.8%
2016 18.627 43.1%
2017 12.520 -48.78%
2018 5.411 -131.38%
2019 4.227.849 99.87%
2020 2.000.483 -111.34%
2021 198.684 -906.87%
2022 8.163.914 97.57%
2023 -3.955.125 306.41%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Amoéba S.A. Assets
Year Assets Growth
2011 1.258.593
2012 1.717.945 26.74%
2013 2.235.539 23.15%
2014 5.551.143 59.73%
2015 14.135 -39172.32%
2016 23.313 39.37%
2017 21.580 -8.03%
2018 13.922 -55.01%
2019 13.840.909 99.9%
2020 13.064.300 -5.94%
2021 14.501.572 9.91%
2022 12.391.632 -17.03%
2023 6.275.538 -97.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Amoéba S.A. Liabilities
Year Liabilities Growth
2011 661.175
2012 770.750 14.22%
2013 1.801.548 57.22%
2014 2.752.126 34.54%
2015 3.536 -77731.62%
2016 4.687 24.54%
2017 9.060 48.27%
2018 8.512 -6.44%
2019 9.613.060 99.91%
2020 11.063.817 13.11%
2021 14.302.888 22.65%
2022 4.227.717 -238.31%
2023 10.230.663 58.68%

Amoéba S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-81.47
Price to Earning Ratio
-0.01x
Price To Sales Ratio
0x
POCF Ratio
-0.01
PFCF Ratio
-7.32
Price to Book Ratio
-0.01
EV to Sales
0
EV Over EBITDA
-7.37
EV to Operating CashFlow
-13.68
EV to FreeCashFlow
-8.55
Earnings Yield
-155.19
FreeCashFlow Yield
-0.14
Market Cap
0,03 Bil.
Enterprise Value
0,03 Bil.
Graham Number
383.69
Graham NetNet
-168.33

Income Statement Metrics

Net Income per Share
-81.47
Income Quality
0.56
ROE
-2.92
Return On Assets
-0.64
Return On Capital Employed
23.05
Net Income per EBT
0.92
EBT Per Ebit
0.93
Ebit per Revenue
0
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-45.25
Free CashFlow per Share
-72.34
Capex to Operating CashFlow
-0.6
Capex to Revenue
0
Capex to Depreciation
2.63
Return on Invested Capital
-8.03
Return on Tangible Assets
-0.64
Days Sales Outstanding
0
Days Payables Outstanding
345.11
Days of Inventory on Hand
161.72
Receivables Turnover
0
Payables Turnover
1.06
Inventory Turnover
2.26
Capex per Share
27.09

Balance Sheet

Cash per Share
10,55
Book Value per Share
-80,31
Tangible Book Value per Share
-81.1
Shareholders Equity per Share
-80.31
Interest Debt per Share
92.93
Debt to Equity
-1.13
Debt to Assets
0.71
Net Debt to EBITDA
-1.06
Current Ratio
0.41
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-302672
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
225447.5
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Amoéba S.A. Dividends
Year Dividends Growth

Amoéba S.A. Profile

About Amoéba S.A.

Amoéba S.A. develops and sells biocidal and fungicide products. It is developing around multiple applications using the amoeba Willaertia magna C2c Maky in the prevention of microbiological risk for water treatment, human wounds, and plant protection. The company was founded in 2010 and is headquartered in Chassieu, France.

CEO
Mr. Jean-Francois Doucet
Employee
22
Address
38 Avenue de FrEres Montgolfier
Chassieu, 69680

Amoéba S.A. Executives & BODs

Amoéba S.A. Executives & BODs
# Name Age
1 Dr. Sandrine Troussieux
Scientific Director
70
2 Mr. Jean-Francois Doucet
General Director
70

Amoéba S.A. Competitors

Gaussin SA Logo
Gaussin SA

ALGAU.PA

(0.8)
The Blockchain Group Logo
The Blockchain Group

ALTBG.PA

(1.5)
Drone Volt SA Logo
Drone Volt SA

ALDRV.PA

(1.0)
GenSight Biologics S.A. Logo
GenSight Biologics S.A.

SIGHT.PA

(1.8)
Europlasma S.A. Logo
Europlasma S.A.

ALEUP.PA

(0.5)